Breast Cancer Liquid Biopsy Market Size 2024-2028 

The breast cancer liquid biopsy market size is forecast to increase by USD 534.8 million, at a CAGR of 18.06% between 2023 and 2028. In the realm of healthcare, the rise in breast cancer diagnoses worldwide necessitates innovative solutions for effective treatment. The focus on personalized medicine in cancer care is increasingly significant, as individualized therapies cater to unique patient needs, enhancing treatment outcomes. Furthermore, the demand for minimally invasive therapies is growing, as they offer reduced recovery time, fewer complications, and improved patient comfort. Companies like XYZ Healthcare are answering this call with their key offering: a revolutionary breast cancer treatment utilizing personalized medicine and minimally invasive techniques. By combining advanced genomic profiling and targeted therapy, XYZ Healthcare aims to provide patients with optimized, effective, and less invasive breast cancer treatments.

What will be the Size of the Market During the Forecast Period?

For More Highlights About this Report, Request Free Sample

Market Dynamic and Customer Landscape

The market is witnessing significant growth due to the increasing demand for minimally invasive diagnostic methods for breast cancer. The market is primarily driven by the use of advanced technologies such as Cell-free DNA (cfDNA) and Circulating Tumor Cells (CTCs) for molecular testing. These technologies enable the detection of circulating biomarkers, including extracellular vesicles, in the bloodstream, providing valuable information for breast cancer diagnosis, treatment, and prognostics. The market comprises various stakeholders, including laboratories, hospitals, physician laboratories, reference laboratories, and public health laboratories. The demand for liquid biopsy tests is increasing due to their ability to provide real-time information on the tumor's genetic profile, enabling personalized treatment plans for breast cancer patients.

Also, the market includes consumables and kits, such as reagent kits, used for cfDNA and CTC isolation and analysis. Also, the market includes traditional tests like Polymerase Chain Reaction (PCR) and Next-Generation Sequencing (NGS) for molecular testing. The World Health Organization (WHO) is also promoting the use of liquid biopsy for breast cancer diagnosis and treatment. In conclusion, the market is expected to grow significantly due to the increasing demand for minimally invasive diagnostic methods and personalized treatment plans for breast cancer patients. The market includes various stakeholders, including laboratories, hospitals, and research institutes, and comprises technologies such as cfDNA, CTCs, PCR, and NGS.

Key Market Driver

Growing prevalence of breast cancer cases is notably driving market growth. Breast cancer is a significant health concern worldwide, accounting for a considerable number of deaths globally. Among various types of cancer, breast cancer is the most common in women, particularly in the geriatric population, with around 9% of women aged 65 and above being diagnosed in 2021. Younger women are also susceptible, as evidenced by the 12% of new breast cancer cases reported in the US for women below 45 years of age in July 2021. The diagnostic segment in the breast cancer market is witnessing substantial growth due to the increasing demand for early and accurate detection.

Moreover, prognostics and risk assessment are crucial aspects of breast cancer management, leading to the growing adoption of personalized therapeutics. Liquid biopsies, an alternative to solid tissue biopsies, offer several advantages, including minimally invasive procedures, real-time monitoring, and improved patient compliance. These factors are expected to drive the growth of the breast cancer liquid biopsy market. Thus, such factors are driving the growth of the market during the forecast period.

Significant Market Trends

Programs to detect breast cancer at the early stages is the key trend in the market. Government and private organizations' funding and grants are significantly contributing to the advancement of innovative products for breast cancer screening. These solutions, including prognostics and risk assessment tools in the diagnostics segment, aim to provide superior preventive care for patients. For instance, the European Commission has supported projects like BRIDGES and B-CAST.

Further, BRIDGES utilizes next-generation sequencing to identify women at high risk of breast cancer based on their DNA variations or mutations. This enables high-risk patients to undergo comprehensive evaluations and take preventive measures accordingly. B-CAST focuses on breast cancer stratification, enabling precise identification of individuals' breast cancer risks. These advanced tools are essential for personalized therapeutics and improving overall breast cancer management. Thus, such trends will shape the growth of the market during the forecast period.

Major Market Challenge

High cost of breast biopsy is the major challenge that affects the growth of the market. Breast cancer is a significant health concern worldwide, leading to an increased focus on early detection and accurate diagnosis. The diagnostics segment of the breast cancer market is witnessing growth due to the rising adoption of advanced technologies for prognostics and risk assessment. Liquid biopsies, a newer approach in breast cancer diagnostics, are gaining traction due to their ability to provide real-time information on the presence and progression of cancer cells in the body. These tests are less invasive than solid tissue biopsies and offer a more personalized therapeutic approach.

Needle biopsies, guided by imaging techniques like mammograms, ultrasound, and MRIs, continue to be the primary method for breast cancer diagnosis. These procedures enable healthcare professionals to obtain a sample of the breast tissue for further examination, providing valuable insights for patient care and treatment planning. Hence, the above factors will impede the growth of the market during the forecast period

Exclusive Customer Landscape

The market forecasting report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth analysis strategies.

 Customer Landscape

Key Companies & Market Insights

Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.

Bio Rad Laboratories Inc. - The company offers breast cancer liquid biopsy that includes Breast Tumor Antigen which helps in protecting mucous membranes, signal transduction, and modulation of the immune system.

The market research and growth report also includes detailed analyses of the competitive landscape of the market and information about key companies, including:

• Biocept Inc.
• Biodesix Inc.
• Cardiff Oncology Inc.
• Epic Sciences Inc.
• Exact Sciences Corp.
• F. Hoffmann La Roche Ltd.
• Fluxion Biosciences Inc.
• Guardant Health Inc.
• Illumina Inc.
• Isogen Life Science BV
• Johnson and Johnson Services Inc.
• Lucence Health Inc.
• Menarini Silicon Biosystems SpA
• MiRXES Pte Ltd.
• Myriad Genetics Inc.
• NeoGenomics Laboratories Inc.
• QIAGEN NV
• Sysmex Inostics Inc.
• Thermo Fisher Scientific Inc.

Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.

Market Segmentation

By Product Type 

The reagent kits segment is estimated to witness significant growth during the forecast period. The global Breast Cancer Liquid Biopsy Market is experiencing significant growth due to the increasing adoption of minimally invasive diagnostic tests and the advancements in molecular testing technologies. Consumables and kits, specifically reagent kits, hold a prominent position in this market. The availability of novel reagents that facilitate the analysis of circulating biomarkers, such as cell-free DNA and circulating tumor cells, and target enrichment, is driving the segment's growth. Additionally, an increase in funding for research and development of breast cancer liquid biopsy and the approval of new reagent kits are contributing factors. Other factors fueling the market include the surge in demand for these tests, the rise in the number of breast cancer cases worldwide, and the preference for liquid biopsies over traditional tissue biopsies.

Get a glance at the market share of various regions Download the PDF Sample

The reagent kits segment was the largest and was valued at USD 156.90 million in 2018. Healthcare facilities, including laboratories in hospitals, physician offices, reference laboratories, public health laboratories, research institutes, and small molecular laboratories, are major consumers of these reagents. Skilled pathologists, technicians, and molecular biologists are essential in performing these tests and interpreting the results. The use of advanced technologies, such as polymerase chain reaction (PCR) and next-generation sequencing, further enhances the diagnostic accuracy of these tests. Furthermore, the emergence of medical tourism and pre-screening programs is expected to expand the market's reach. Extracellular vesicles, circulating tumor DNA, and proteins are some of the key genetic material and biomarkers used in breast cancer liquid biopsy. The market's growth is also driven by the potential of these tests to provide valuable information on treatment response and disease progression.

Regional Analysis

For more insights on the market share of various regions Download PDF Sample now!

North America is estimated to contribute 55% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period. The market encompasses the consumption of Consumables and Kits used in the identification and analysis of Cell free DNA, Circulating Tumor Cells, and other biomarkers in bodily fluids such as blood. These tests are conducted in various healthcare facilities including Hospitals, Physician Laboratories, Reference Laboratories, Public Health Laboratories, Research Institutes, Small Molecular Laboratories, and Pathology Laboratories.

In addition, the genetic material and proteins extracted from these samples provide valuable insights into genetic mutations, treatment response, and disease progression. Skilled pathologists, technicians, and molecular biologists utilize advanced techniques like Polymerase chain reaction (PCR) and Next generation sequencing (NGS) for molecular testing. High risk populations are increasingly turning to circulating biomarkers, such as circulating tumor DNA (ctDNA) and extracellular vesicles, for early detection and personalized breast cancer treatment. Traditional tests like Surgical tissue biopsy are being complemented by these minimally invasive, less risky alternatives. Biomarker discovery and validation are crucial for the development of new diagnostics and therapeutics in the field of breast cancer.

Segment Overview

The market research report provides comprehensive data (region wise segment analysis), with forecasts and estimates in "USD million" for the period 2024 to 2028, as well as historical data from 2018 to 2022 for the following segments.

• Product Type Outlook
  • Reagent kits
  • Instruments
  • Services

• Application Outlook
  • Large Enterprise
  • Small and Medium Enterprise

• Region Outlook
  • North America
    • The U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • France
    • Rest of Europe
  • Asia
    • China
    • India
  • Rest of World (ROW)
    • Brazil
    • Argentina
    • Australia

You may also interested in below market reports:

• Liquid Biopsy Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, Canada, Germany, UK, Japan - Size and Forecast
• Breast Cancer Liquid Biopsy Market by Product Type and Geography - Forecast and Analysis
• Breast Biopsy Devices Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, Germany, France, China, Canada - Size and Forecast

Market Analyst Overview

A Revolutionary Approach in Early Detection and Personalized Treatment Breast cancer is a leading cause of morbidity and mortality worldwide. Traditional methods for breast cancer diagnosis include tissue biopsies, which can be invasive and sometimes inaccurate. However, the advent of liquid biopsy has brought about a paradigm shift in breast cancer diagnosis and treatment. Liquid biopsy refers to the analysis of bodily fluids, primarily blood, for the presence of circulating tumor cells (CTCs), cell-free DNA (cfDNA), and other biomarkers. The market is witnessing significant growth due to the advantages it offers over traditional tests. Consumables and kits used in liquid biopsy include reagent kits for cfDNA and CTC isolation, molecular testing for biomarker detection, and extracellular vesicles for molecular analysis. The market is segmented based on the type of laboratories, including hospitals, physician laboratories, reference laboratories, public health laboratories, research institutes, small molecular laboratories, and pathology laboratories.

Breast cancer biomarkers, such as genetic material and proteins, are essential in the detection of genetic mutations, treatment response, and disease progression. Skilled pathologists, technicians, and molecular biologists are crucial in the interpretation of liquid biopsy results. The market is driven by the increasing prevalence of breast cancer, the need for early detection and personalized treatment, and the availability of advanced technologies like Polymerase chain reaction (PCR) and Next-generation sequencing (NGS). Medical tourism and pre-screening programs are also contributing to the market growth. In conclusion, the market is poised for significant growth due to its advantages over traditional tests and the increasing demand for early and accurate diagnosis and personalized treatment.

Further, the market is advancing with the utilization of Circulating Biomarkers, particularly Extracellular Vesicles circulating biomarker , in non-invasive medical procedures for early detection and monitoring. These biomarkers play a pivotal role in screening programs conducted in hospitals and physician laboratories, offering a non-invasive alternative to traditional methods. Genome-based diagnostic procedures enhance precision, managed by skilled Molecular Diagnostics technicians. This approach supports pre-screening programs for efficient detection of breast cancer biomarkers, potentially revolutionizing non invasive breast cancer treatment. The market's growth is propelled by the demand for minimally invasive diagnostic tools that provide accurate and timely insights into cancer progression and treatment efficacy, improving patient outcomes and quality of life.

Download PDF Sample

What are the Key Data Covered in this Market Research Report?

• CAGR of the market during the forecast period
• Detailed information on factors that will drive the market growth and forecasting between 2024 and 2028
• Precise estimation of the size of the market  and its contribution of the market in focus to the parent market
• Accurate predictions about upcoming market growth and trends and changes in consumer behavior
• Growth of the market across North America, Europe, Asia, and Rest of World (ROW)
• Thorough analysis of the market’s competitive landscape and detailed information about companies
• Comprehensive analysis of factors that will challenge the growth of market companies